Postmenopausal vaginal bleeding in women using hormone replacement therapy.

Area of Science:

• Gynecologic Oncology
• Reproductive Endocrinology

Background:

• Postmenopausal vaginal bleeding is a concerning symptom requiring investigation.
• Hormone replacement therapy (HRT) is commonly used for menopausal symptoms.
• The association between HRT use and endometrial cancer risk requires clarification, especially in symptomatic women.

Purpose of the Study:

• To evaluate the risk of endometrial cancer in postmenopausal women with vaginal bleeding who are using estrogen-progestogen hormone replacement therapy (HRT).
• To determine if the duration of HRT use influences the risk of endometrial cancer diagnosis in this patient group.

Main Methods:

• A cross-sectional study was conducted at a UK gynaecological oncology centre.
• Consecutive women presenting with postmenopausal vaginal bleeding were analyzed.
• Endometrial cancer diagnosis was the primary outcome measure.

Main Results:

• Out of 4847 women, 15.5% used combined HRT, and 6.1% were diagnosed with endometrial carcinoma.
• Women using HRT showed a significantly lower likelihood of endometrial cancer diagnosis (adjusted OR = 0.229, P < 0.0001).
• Longer HRT duration showed a non-significant trend towards increased endometrial cancer risk.

Conclusions:

• Combined HRT use is associated with a significantly reduced risk of endometrial cancer in postmenopausal women with vaginal bleeding.
• The findings suggest a protective effect of combined HRT against endometrial cancer in this symptomatic population.